BeiGene
2025.06.04
16:37
FTSE Russell announced the results of the June 2025 quarterly review. Jiangsu Bank was included in the FTSE China A50 Index and Great Wall Motor was excluded; BeiGene, Yili Group, SAIC Group, SERES, Huichuan Technology and other stocks were included in the list of alternative stocks.
16:37
FTSE Russell announces June 2025 quarterly review results, FTSE China A50 Index includes Jiangsu Bank
FTSE Russell announced the results of the June 2025 quarterly review. Jiangsu Bank was included in the FTSE China A50 Index and Great Wall Motor was excluded; BeiGene, Yili Group, SAIC Group, SERES, Huichuan Technology and other stocks were included in the list of alternative stocks.
2025.05.29
16:38
The National Medical Products Administration conditionally approved the marketing of Zenedatumumab for injection
The National Medical Products Administration has conditionally approved the marketing of Zenidatuzumab for injection (trade name: Bhean) submitted by BeiGene (Suzhou) Biotechnology Co., Ltd. through the priority review and approval procedure. It is suitable for patients with unresectable locally advanced or metastatic biliary tract cancer with high HER2 expression (IHC3+) who have previously received systemic treatment. The launch of this product provides a new treatment option for related patients.
2025.05.27
21:26
BeiGene: Change of registered place of business to Switzerland
BeiGene announced that the company has changed its registered place from the Cayman Islands to Switzerland by continuing to register as a stock company in Switzerland on May 27, 2025. From the effective date of the continued registration, the company will apply the articles of association formulated in accordance with Swiss law, and the English name will be changed to BeOne Medicines Ltd., while the Chinese name will remain unchanged. Ernst & Young AG of Switzerland will serve as the company's Swiss statutory auditor until the date of the first annual general meeting of shareholders after the completion of the company's continued registration. Ernst & Young Hua Ming will continue to serve as the company's A-share audit agency.
2025.05.26
09:24
Many stocks in the Hong Kong biotechnology sector opened higher, with Zhaoyan Pharmaceutical (06127.HK) rising more than 4%, Tiger Pharmaceuticals (03347.HK) rising nearly 3%, Junshi Biosciences (01877.HK), BeiGene (06160.HK) and others following suit.
2025.05.22
09:37
The Hong Kong stock market's biopharmaceutical sector fell back and weakened, with Tiger Pharmaceuticals (03347.HK) falling nearly 3%, Rongchang Biopharma (09995.HK) falling more than 2%, BeiGene (06160.HK), WuXi AppTec (02359.HK) and others following suit.
2025.05.16
05:05
Hillhouse Capital's HHLR increased its Chinese assets in the first quarter and newly increased its holdings of multiple Chinese concept stocks
HHLR Advisors, an independent fund management platform under Hillhouse Capital that focuses on secondary market investment, announced its U.S. stock holdings as of the end of the first quarter of 2025. The 13F document shows that the total market value of HHLR's holdings in the first quarter increased from US$2.887 billion at the end of the previous quarter to US$3.539 billion, an increase of nearly 23%. Data shows that in the first quarter, HHLR continued to increase its allocation of Chinese assets, and newly entered and increased its holdings of nearly 20 Chinese concept stocks, including 10 companies such as Atour Group, Huazhu Group, Baidu, Yuchai International, Ideal Auto, Boss Direct Recruitment, and Ecarx Technology, as well as 8 companies such as Futu Holdings, Pinduoduo, NetEase, Beike, JD.com, Ctrip, and ZTO Express. As of the end of the first quarter of 2025, HHLR's top ten holdings were: Pinduoduo, Alibaba, Futu Holdings, BeiGene, NetEase, Beike, Legend Biotech, JD.com, Vipshop, and WNS HLDGS LTD, with Chinese concept stocks accounting for 9 seats. HHLR reduced its holdings in companies such as Alibaba and BeiGene in the first quarter.
2025.05.15
12:45
Hillhouse Capital reduces its stake in BeiGene. Industry insiders: The fund expires and LPs have a need for distribution. This is a normal exit
BeiGene issued an announcement stating that the company's shareholder HHLRFund, LP and its affiliated entities reduced their holdings of the company's overseas outstanding shares by 16 million shares on May 9, and their shareholding ratio dropped from 6.03% to 4.89%, and they are no longer shareholders holding more than 5% of the company's shares. It is worth noting that as of September 30, 2024, HHLRFund, LP and its affiliated entities held 10.31% of the shares. This means that in more than 7 months, Hillhouse's share reduction ratio was as high as 5.42 percentage points, and it sold more than half of its holdings. An industry insider told reporters that the investment period of a fund generally does not exceed 10 years. Hillhouse's reduction in holdings this time is mainly because it has invested in BeiGene for more than 10 years. The fund is now due and LP has a distribution demand. This is a normal exit of the fund. "For investment institutions, the business model is to invest in different targets, lock in profits and exit, and then look at new investments to make asset reallocations."
2025.05.14
21:53
BeiGene: Shareholder HHLR Fund, LP reduced its stake to 4.89%
BeiGene announced that shareholder HHLR Fund, LP and its affiliated entities reduced their holdings of the company's overseas circulating shares by 16 million shares on May 9, 2025, reducing the total number of shares held to 68.5511 million shares. The shareholding ratio changed from 6.03% to 4.89%, and they are no longer shareholders holding more than 5% of the company's shares.
07:37
BeiGene: Will allot and issue 133 million new shares to its wholly-owned subsidiary BGNC2
BeiGene announced on the Hong Kong Stock Exchange that it will allot and issue 133 million new shares to its wholly-owned subsidiary BGNC2.
2025.05.13
09:23
Hong Kong stocks' innovative drug sector rebounded, with BeiGene (06160.HK) rising nearly 7%, Rongchang Biopharma (09995.HK) and Innovent Biologics (01801.HK) rising more than 4%, and CSPC Pharmaceutical Group (01093.HK) rising more than 1%.
09:23
Hong Kong stocks' innovative drug sector rebounded, with BeiGene rising nearly 7%
The Hong Kong stock market's innovative drug sector rebounded, with BeiGene rising nearly 7%, Rongchang Biopharma and Innovent Biologics rising more than 4%, and Shijiazhuang Pharmaceutical Group, Corning Life Sciences, and WuXi Biologics rising more than 1%.
2025.05.12
15:01
A-share closing review: ChiNext Index opened higher and rose 2.63%, Apple concept stocks continued to strengthen in the afternoon
The three major A-share indices rose collectively today. As of the close, the Shanghai Composite Index rose 0.82%, the Shenzhen Component Index rose 1.72%, the ChiNext Index rose 2.63%, and the Beijing Stock Exchange 50 Index rose 2.89%. The total market turnover was 1,340.9 billion yuan, an increase of 118.5 billion yuan from the previous day. More than 4,100 stocks rose in the entire market. In terms of sector themes, the military industry, robots, Apple industry chain, rail transit equipment, photovoltaic equipment, and solid-state battery sectors led the gains; precious metals, agriculture, innovative drugs, electricity, and beverage manufacturing sectors led the declines. On the market, military stocks rose again today, with more than 20 stocks such as Qifeng Precision, Kunchuan Intelligent, AVIC Chengfei, Chenxi Aviation, and Aerospace Nanhu hitting the daily limit. Affected by the good news of the Sino-US negotiations, Apple industry chain stocks rebounded collectively today, with Blue Technology, Luxshare Precision, and Goertek leading the gains. Robots were also active, with Tosda 20cm hitting the daily limit, Efort rising more than 10%, and Sanfeng Intelligent, Yijiahe, and Estun following suit. Innovative drug concept stocks collectively weakened today, with Mywell Biopharma falling more than 10%, BeiGene falling more than 9%, and Sulfamethoxazole, Salubris, and Hengrui Medicine all falling. Gold stocks also lagged behind, with Western Gold, Sichuan Gold, and Xiaocheng Technology leading the decline.
14:38
Hong Kong stocks' innovative drug sector continued to fall, with BeiGene falling more than 10%
The Hong Kong stock market's innovative drug sector continued to decline, with BeiGene and Ascletis Pharmaceuticals-B both falling by more than 10%, Innovent Biologics falling by more than 7%, and Zhaoyan Pharmaceutical and CSPC Pharmaceutical Group leading the decline.
12:00
Hong Kong Stock Midday Review: Hang Seng Index rose 0.93%, Hang Seng Technology Index rose 1.91%
At the close of Hong Kong stocks at noon, the Hang Seng Index rose 0.93% and the Hang Seng Technology Index rose 1.91%. Apple concept stocks led the gains, with Sunny Optical Technology rising more than 10% and AAC Technologies rising more than 9%. The innovative drug sector led the decline, with Ascletis Pharmaceuticals-B falling more than 8% and BeiGene falling more than 7%.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
According to Axios: Meta Platforms (META.O) split its artificial intelligence team into two departments.

2025-05-27

South Korea's exports fell 1.3% in May from a year earlier

2025-06-01

FF:FX Super One received another 600 pre-orders, totaling 2,500 units

2025-06-02

Tesla's (TSLA.O) sales in Sweden rose 53.7% in May from a year earlier.

2025-06-02

Nvidia CEO Jensen Huang: China's artificial intelligence market will continue to develop, with or without American chips.

2025-05-29

ASIA TECH WIRE

Grasp technology trends

Download